PortfoliosLab logoPortfoliosLab logo
BWAY vs. BSX
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Performance

BWAY vs. BSX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in BrainsWay Ltd. (BWAY) and Boston Scientific Corporation (BSX). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

BWAY vs. BSX - Yearly Performance Comparison


2026 (YTD)2025202420232022202120202019
BWAY
BrainsWay Ltd.
42.80%101.70%45.52%162.35%-67.92%2.12%-22.67%-12.08%
BSX
Boston Scientific Corporation
-34.98%6.75%54.51%24.94%8.92%18.16%-20.50%29.53%

Fundamentals

Market Cap

BWAY:

$284.65M

BSX:

$92.74B

EPS

BWAY:

$0.24

BSX:

$1.93

PE Ratio

BWAY:

57.24

BSX:

32.07

PEG Ratio

BWAY:

0.16

BSX:

0.72

PS Ratio

BWAY:

8.37

BSX:

4.62

PB Ratio

BWAY:

3.89

BSX:

3.83

Total Revenue (TTM)

BWAY:

$52.32M

BSX:

$20.08B

Gross Profit (TTM)

BWAY:

$39.46M

BSX:

$13.85B

EBITDA (TTM)

BWAY:

$10.01M

BSX:

$4.91B

Returns By Period

In the year-to-date period, BWAY achieves a 42.80% return, which is significantly higher than BSX's -34.98% return.


BWAY

1D
2.18%
1M
14.65%
YTD
42.80%
6M
78.80%
1Y
195.54%
3Y*
149.20%
5Y*
23.72%
10Y*

BSX

1D
-1.20%
1M
-18.66%
YTD
-34.98%
6M
-35.32%
1Y
-38.76%
3Y*
7.41%
5Y*
9.95%
10Y*
12.59%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

BWAY vs. BSX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BWAY
BWAY Risk / Return Rank: 9797
Overall Rank
BWAY Sharpe Ratio Rank: 9898
Sharpe Ratio Rank
BWAY Sortino Ratio Rank: 9898
Sortino Ratio Rank
BWAY Omega Ratio Rank: 9595
Omega Ratio Rank
BWAY Calmar Ratio Rank: 9898
Calmar Ratio Rank
BWAY Martin Ratio Rank: 9898
Martin Ratio Rank

BSX
BSX Risk / Return Rank: 33
Overall Rank
BSX Sharpe Ratio Rank: 11
Sharpe Ratio Rank
BSX Sortino Ratio Rank: 44
Sortino Ratio Rank
BSX Omega Ratio Rank: 33
Omega Ratio Rank
BSX Calmar Ratio Rank: 77
Calmar Ratio Rank
BSX Martin Ratio Rank: 00
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BWAY vs. BSX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for BrainsWay Ltd. (BWAY) and Boston Scientific Corporation (BSX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


BWAYBSXDifference

Sharpe ratio

Return per unit of total volatility

3.79

-1.24

+5.04

Sortino ratio

Return per unit of downside risk

4.38

-1.64

+6.02

Omega ratio

Gain probability vs. loss probability

1.50

0.75

+0.76

Calmar ratio

Return relative to maximum drawdown

10.22

-0.90

+11.13

Martin ratio

Return relative to average drawdown

26.15

-2.54

+28.69

BWAY vs. BSX - Sharpe Ratio Comparison

The current BWAY Sharpe Ratio is 3.79, which is higher than the BSX Sharpe Ratio of -1.24. The chart below compares the historical Sharpe Ratios of BWAY and BSX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading graphics...

Sharpe Ratios by Period


BWAYBSXDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

3.79

-1.24

+5.04

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.38

0.41

-0.03

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.47

Sharpe Ratio (All Time)

Calculated using the full available price history

0.22

0.22

+0.01

Correlation

The correlation between BWAY and BSX is 0.16, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Dividends

BWAY vs. BSX - Dividend Comparison

Neither BWAY nor BSX has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

BWAY vs. BSX - Drawdown Comparison

The maximum BWAY drawdown since its inception was -88.14%, roughly equal to the maximum BSX drawdown of -89.15%. Use the drawdown chart below to compare losses from any high point for BWAY and BSX.


Loading graphics...

Drawdown Indicators


BWAYBSXDifference

Max Drawdown

Largest peak-to-trough decline

-88.14%

-89.15%

+1.01%

Max Drawdown (1Y)

Largest decline over 1 year

-18.27%

-42.67%

+24.40%

Max Drawdown (5Y)

Largest decline over 5 years

-87.44%

-42.67%

-44.77%

Max Drawdown (10Y)

Largest decline over 10 years

-43.49%

Current Drawdown

Current decline from peak

-2.51%

-42.67%

+40.16%

Average Drawdown

Average peak-to-trough decline

-37.91%

-38.71%

+0.80%

Ulcer Index

Depth and duration of drawdowns from previous peaks

7.14%

15.18%

-8.04%

Volatility

BWAY vs. BSX - Volatility Comparison

BrainsWay Ltd. (BWAY) has a higher volatility of 14.48% compared to Boston Scientific Corporation (BSX) at 11.24%. This indicates that BWAY's price experiences larger fluctuations and is considered to be riskier than BSX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading graphics...

Volatility by Period


BWAYBSXDifference

Volatility (1M)

Calculated over the trailing 1-month period

14.48%

11.24%

+3.24%

Volatility (6M)

Calculated over the trailing 6-month period

37.15%

27.06%

+10.09%

Volatility (1Y)

Calculated over the trailing 1-year period

52.01%

31.28%

+20.73%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

61.92%

24.22%

+37.70%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

61.69%

26.76%

+34.93%

Financials

BWAY vs. BSX - Financials Comparison

This section allows you to compare key financial metrics between BrainsWay Ltd. and Boston Scientific Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.001.00B2.00B3.00B4.00B5.00BAprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober
14.64M
5.29B
(BWAY) Total Revenue
(BSX) Total Revenue
Values in USD except per share items

BWAY vs. BSX - Profitability Comparison

The chart below illustrates the profitability comparison between BrainsWay Ltd. and Boston Scientific Corporation over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

60.0%65.0%70.0%75.0%80.0%AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober
76.4%
74.5%
Portfolio components
BWAY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, BrainsWay Ltd. reported a gross profit of 11.19M and revenue of 14.64M. Therefore, the gross margin over that period was 76.4%.

BSX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Boston Scientific Corporation reported a gross profit of 3.94B and revenue of 5.29B. Therefore, the gross margin over that period was 74.5%.

BWAY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, BrainsWay Ltd. reported an operating income of 1.93M and revenue of 14.64M, resulting in an operating margin of 13.2%.

BSX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Boston Scientific Corporation reported an operating income of 1.21B and revenue of 5.29B, resulting in an operating margin of 22.8%.

BWAY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, BrainsWay Ltd. reported a net income of 2.95M and revenue of 14.64M, resulting in a net margin of 20.2%.

BSX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Boston Scientific Corporation reported a net income of 668.00M and revenue of 5.29B, resulting in a net margin of 12.6%.